Financhill
Buy
67

TWST Quote, Financials, Valuation and Earnings

Last price:
$32.47
Seasonality move :
-1.03%
Day range:
$30.42 - $33.21
52-week range:
$23.30 - $55.33
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
5.24x
P/B ratio:
4.24x
Volume:
1.2M
Avg. volume:
1.7M
1-year change:
-37.42%
Market cap:
$2B
Revenue:
$376.6M
EPS (TTM):
-$1.31

Analysts' Opinion

  • Consensus Rating
    Twist Bioscience Corp. has received a consensus rating of Buy. The company's average rating is a Buy based on 6 Buy ratings, 1 Hold rating, and 0 Sell ratings.
  • Price Target Upside
    According to analysts' consensus price target of $35.63, Twist Bioscience Corp. has an estimated upside of 8.58% from its current price of $32.81.
  • Price Target Downside
    According to analysts, the lowest downside price target is $32.00 representing 100% downside risk from its current price of $32.81.

Fair Value

  • According to the consensus of 7 analysts, Twist Bioscience Corp. has 8.58% upside to fair value with a price target of $35.63 per share.

TWST vs. S&P 500

  • Over the past 5 trading days, Twist Bioscience Corp. has overperformed the S&P 500 by 3.38% suggesting its relative strength compared to the major market average is strong at this time.

Share Buyback

  • Twist Bioscience Corp. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • Twist Bioscience Corp. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Twist Bioscience Corp. reported revenues of $99M.

Earnings Growth

  • Twist Bioscience Corp. has grown year-over-year earnings for 5 quarters straight. In the most recent quarter Twist Bioscience Corp. reported earnings per share of -$0.45.
Enterprise value:
1.8B
EV / Invested capital:
3.37x
Price / LTM sales:
5.24x
EV / EBIT:
--
EV / Revenue:
4.91x
PEG ratio (5yr expected):
-3.49x
EV / Free cash flow:
-24.45x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$191M
Return On Assets:
-12.51%
Net Income Margin (TTM):
-20.63%
Return On Equity:
-16.74%
Return On Invested Capital:
-14.27%
Operating Margin:
-30.24%
Trailing 12 Months Fiscal Quarters
Period Ending 2023-09-30 2024-09-30 2025-09-30 2024-09-30 2025-09-30
Income Statement
Revenue $245.1M $313M $376.6M $84.7M $99M
Gross Profit $89.7M $133.3M $191M $38.2M $50.8M
Operating Income -$206.9M -$175.9M -$136.3M -$36M -$29.9M
EBITDA -$176.5M -$144.5M -$111.7M -$29.4M -$23.9M
Diluted EPS -$3.60 -$3.60 -$1.31 -$0.59 -$0.45
Period Ending 2021-09-30 2022-09-30 2023-09-30 2024-09-30 2025-09-30
Balance Sheet
Current Assets $546.5M $596.5M $424.3M $346.8M $333M
Total Assets $702.1M $961.4M $776.4M $614.3M $641.9M
Current Liabilities $63.1M $90.7M $73.3M $71M $91.4M
Total Liabilities $121.3M $172M $153M $141.6M $168.9M
Total Equity $580.8M $789.4M $623.4M $472.7M $473M
Total Debt $62.9M $81.3M $79.2M $70.2M $61.8M
Trailing 12 Months Fiscal Quarters
Period Ending 2023-09-30 2024-09-30 2025-09-30 2024-09-30 2025-09-30
Cash Flow Statement
Cash Flow Operations -$142.5M -$64.1M -$47.6M -$15.3M -$11.8M
Cash From Investing $50.6M -$3.1M -$24.8M -$1.3M -$12.4M
Cash From Financing $911K $6.9M $28.5M $3.6M $5.6M
Free Cash Flow -$170.3M -$69.2M -$75.6M -$17.3M -$24.2M
TWST
Sector
Market Cap
$2B
$28.8M
Price % of 52-Week High
59.3%
51.13%
Dividend Yield
0%
0%
Shareholder Yield
-0.66%
-1.32%
1-Year Price Total Return
-37.42%
-20.64%
Beta (5-Year)
2.242
0.520
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years

Technicals

8-day SMA
Buy
Level $30.96
200-day SMA
Sell
Level $33.17
Bollinger Bands (100)
Buy
Level 26.56 - 32.98
Chaikin Money Flow
Buy
Level 47M
20-day SMA
Buy
Level $29.60
Relative Strength Index (RSI14)
Buy
Level 58.88
ADX Line
Buy
Level 13.24
Williams %R
Sell
Level -4.0363
50-day SMA
Buy
Level $30.45
MACD (12, 26)
Buy
Level 0.24
25-day Aroon Oscillator
Sell
Level -40
On Balance Volume
Sell
Level -4.8M

Financial Scores

Buy
Altman Z-Score (Annual)
Level (3.5204)
Buy
CA Score (Annual)
Level (-0.0473)
Buy
Beneish M-Score (Annual)
Level (-2.2862)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (0.6284)
Buy
Piotroski F Score (Annual)
Level (5)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (4)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Twist Bioscience Corp. engages in the development of a proprietary semiconductor-based synthetic DNA manufacturing process. It operates through the following geographical segments: Americas, EMEA, and APAC. The Americas segment consists of the United States of America, Canada, Mexico, and South America. The EMEA segment includes Europe, Middle East, and Africa. The APAC segment focuses on Japan, China, South Korea, India, Singapore, Malaysia, and Australia. The company was founded by William Marine Banyai, Emily Marine Leproust, and Bill James Peck in 2013 and is headquartered in San Francisco, CA.

Stock Forecast FAQ

In the current month, TWST has received 6 Buy ratings 1 Hold ratings, and 0 Sell ratings. The TWST average analyst price target in the past 3 months is $35.63.

  • Where Will Twist Bioscience Corp. Stock Be In 1 Year?

    According to analysts, the consensus estimate is that Twist Bioscience Corp. share price will rise to $35.63 per share over the next 12 months.

  • What Do Analysts Say About Twist Bioscience Corp.?

    Analysts are divided on their view about Twist Bioscience Corp. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Twist Bioscience Corp. is a Sell and believe this share price will drop from its current level to $32.00.

  • What Is Twist Bioscience Corp.'s Price Target?

    The price target for Twist Bioscience Corp. over the next 1-year time period is forecast to be $35.63 according to 7 Wall Street analysts, 6 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.

  • Is TWST A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for Twist Bioscience Corp. is a Buy. 6 of 7 analysts rate the stock a Buy at this time.

  • How Can I Buy Shares Of TWST?

    You can purchase shares of Twist Bioscience Corp. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Twist Bioscience Corp. shares.

  • What Is The Twist Bioscience Corp. Share Price Today?

    Twist Bioscience Corp. was last trading at $32.47 per share. This represents the most recent stock quote for Twist Bioscience Corp.. Yesterday, Twist Bioscience Corp. closed at $32.81 per share.

  • How To Buy Twist Bioscience Corp. Stock Online?

    In order to purchase Twist Bioscience Corp. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Amazon an AI Stock?
Is Amazon an AI Stock?

With the market starting to look skittish on pure-play AI…

Google Vs NVIDIA Stock: Which Is Best?
Google Vs NVIDIA Stock: Which Is Best?

Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…

How High Could NVIDIA Stock Go?
How High Could NVIDIA Stock Go?

NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…

Stock Ideas

Buy
52
Is NVDA Stock a Buy?

Market Cap: $4.5T
P/E Ratio: 62x

Buy
61
Is AAPL Stock a Buy?

Market Cap: $4.1T
P/E Ratio: 38x

Buy
63
Is GOOG Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 40x

Alerts

Buy
54
SMX alert for Dec 5

SMX (Security Matters) Plc [SMX] is up 93.62% over the past day.

Sell
15
HOV alert for Dec 5

Hovnanian Enterprises, Inc. [HOV] is down 1.46% over the past day.

Buy
67
NUTX alert for Dec 5

Nutex Health, Inc. [NUTX] is up 1.2% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock